Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMBNASDAQ:ONCTNASDAQ:SBBPNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$17.73-2.2%$14.53$7.75▼$19.93$138.39M0.6227,503 shs82,811 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.79$1.56M1.1886,734 shsN/ASBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsTHTXTheratechnologies$2.30-2.5%$2.60$1.12▼$3.13$108.51M0.56818,514 shs46,406 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-2.15%+3.08%+24.33%+87.22%+33.91%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-92.49%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%THTXTheratechnologies-2.54%-5.74%-13.21%+56.46%+64.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASMBAssembly Biosciences3.6294 of 5 stars3.33.00.04.71.70.00.0ONCTOncternal Therapeutics1.6136 of 5 stars3.10.00.00.00.80.81.3SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.67Moderate Buy$33.0086.13% UpsideONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ATHTXTheratechnologies 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ONCT, THTX, SBBP, and ASMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M4.75N/AN/A$5.25 per share3.38ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04THTXTheratechnologies$85.87M1.23N/AN/A($0.55) per share-4.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ASBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ATHTXTheratechnologies-$8.31M-$0.08N/A32.86N/A-4.18%N/A-0.37%7/9/2025 (Estimated)Latest ONCT, THTX, SBBP, and ASMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ASMBAssembly Biosciences-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A2.052.05ONCTOncternal TherapeuticsN/A2.392.39SBBPStrongbridge Biopharma0.383.002.95THTXTheratechnologiesN/A1.080.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%ONCTOncternal Therapeutics16.05%SBBPStrongbridge Biopharma52.03%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%ONCTOncternal Therapeutics11.20%SBBPStrongbridge Biopharma5.10%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.64 million7.25 millionOptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataSBBPStrongbridge Biopharma7267.83 millionN/AOptionableTHTXTheratechnologies14045.98 millionN/AOptionableONCT, THTX, SBBP, and ASMB HeadlinesRecent News About These CompaniesTheratechnologies Inc. (NASDAQ:THTX) Short Interest UpdateJune 2, 2025 | marketbeat.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 29, 2025 | globenewswire.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comFTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comFSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | businesswire.comTheratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the CompanyApril 11, 2025 | globenewswire.comFuture Pak submits proposals to acquire TheratechnologiesApril 11, 2025 | msn.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc. ...April 11, 2025 | gurufocus.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total ValueApril 11, 2025 | businesswire.comTheratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment SoursApril 9, 2025 | msn.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies receives FDA approval of PAS for EGRIFTA SV sBLAApril 8, 2025 | markets.businessinsider.com3THTX : Examining the Future: Theratechnologies's Earnings OutlookApril 8, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, THTX, SBBP, and ASMB Company DescriptionsAssembly Biosciences NASDAQ:ASMB$17.73 -0.39 (-2.15%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$18.00 +0.27 (+1.53%) As of 07/1/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Theratechnologies NASDAQ:THTX$2.30 -0.06 (-2.54%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.32 +0.02 (+0.65%) As of 07/1/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
